Duopharma Biotech Berhad

Anticipate Expansion in Duopharma Biotech as Leadership Prepares for Transition

Haha94

Invested

Community Contributor

Published

31 Jul 25

Updated

06 Aug 25

Haha94's Fair Value

RM 1.68

22.6% undervalued

06 Aug

RM 1.30

15.0%

-1.5%

Author's Valuation

RM 1.7

22.6% undervalued

Haha94's Fair Value

Narrative

Updates1

Shared on06 Aug 25

Haha94 made no meaningful changes to valuation assumptions.

Haha94'sFair Value

RM 1.7

22.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.37%

Pharma revenue growth rate

1.18%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.45%

Calculation

RM 166.67m

Earnings '30

14.50x

PE Ratio '30

RM 2.42b

Market Cap '30

RM 2.42b

Market Cap '30

961.94m

No. shares '30

RM 2.51

Share Price '30

RM 2.51 Share Price '30

Discounted to 2025 @ 8.38% p.a.

RM 1.68

Fair Value '25